Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Glutaral→

Glutaral Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
111-30-8
Molecular formula
C5H8O2
Molecular weight
100.12 g/mol
Drug class
Aldehyde high-level disinfectant and chemical sterilant
Mechanism of action
Glutaraldehyde alkylates sulfhydryl, hydroxyl, carboxyl and amino groups in microbial proteins and nucleic acids, altering RNA, DNA and protein synthesis and causing microbial inactivation. Sporocidal performance depends on activation, concentration, pH and contact time.
Indications / reported uses
  • High-level disinfection of heat-sensitive medical and surgical equipment, including endoscopes, under validated manufacturer instructions and applicable healthcare infection-control procedures; not a systemic therapeutic drug.

Sources: https://www.cdc.gov/infection-control/hcp/disinfection-sterilization/chemical-disinfectants.html · https://www.cdc.gov/infection-control/media/pdfs/guideline-disinfection-h.pdf

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Aldehyde high-level disinfectant and chemical sterilant

Mechanism of action

Glutaraldehyde alkylates sulfhydryl, hydroxyl, carboxyl and amino groups in microbial proteins and nucleic acids, altering RNA, DNA and protein synthesis and causing microbial inactivation. Sporocidal performance depends on activation, concentration, pH and contact time.

General use cases

  • High-level disinfection of heat-sensitive medical and surgical equipment, including endoscopes, under validated manufacturer instructions and applicable healthcare infection-control procedures; not a systemic therapeutic drug.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Glutaral Environmental Risk Assessment (ERA) (the Glutaral ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.